Concepedia

Ahmad Halwani

AH

32

Publications

6.6K

Citations

22

H-Index

2008

Active since

Affiliations

Huntsman Cancer Institute(Current)

University of Utah

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

University of Pennsylvania

Ahmad Halwani is an author at Huntsman Cancer Institute specializing in medicine, oncology, and immunotherapy.

ORCID

Top concepts

Publications per year

2008–2023

32

Publications

32

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand et al. · Journal of Clinical Oncology · 2016 · 1K citations · Full text

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

, , +6

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Reid W. Merryman, Haesook T. Kim, Pier Luigi Zinzani et al. · Blood · 2017 · 234 citations · Full text

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai et al. · Journal of the National Comprehensive Cancer Network · 2022 · 153 citations · Full text

Rows per page

1–5 of 32